Talphera (TLPH – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Naz Rahman from Maxim Group reiterated a Buy rating on the stock and has a $3.00 price target.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Naz Rahman has given his Buy rating due to a combination of factors surrounding Talphera’s strategic advancements and financial positioning. The company has successfully secured a private placement, raising significant funds that are expected to support its operations through the completion of the Phase 3 trial for Niyad by the end of 2025. This financial stability, coupled with the absence of debt, provides a solid foundation for Talphera’s ongoing and future endeavors.
Moreover, Talphera’s agreement with the FDA to reduce the patient number in its Phase 3 NEPHRO CRRT study from 166 to 70 is a strategic move that accelerates the trial timeline while reducing costs. The company’s focus on optimizing study sites and protocol amendments to expedite enrollment further underscores its commitment to efficient trial execution. Additionally, the potential of Niyad as a regional anticoagulant, supported by extensive overseas data, positions Talphera favorably in the market, reinforcing the Buy recommendation.
TLPH’s price has also changed moderately for the past six months – from $0.690 to $0.490, which is a -28.99% drop .